In:
British Journal of Clinical Pharmacology, Wiley, Vol. 40, No. 3 ( 1995-09), p. 273-276
Abstract:
Prostaglandin E1 (PGE1) (30, 60, 120 micrograms) was administered by intravenous infusion over a 120 min period in an open, three way randomized, cross‐over study to 12 healthy male volunteers. For the evaluation of PGE1, PGE0 and 15‐keto‐PGE0, blood samples were drawn prior to, during and after the infusion. Analytical measurements were performed by gas chromatography/negative ion chemical ionization triple stage quadruple mass spectrometry, a highly specific and sensitive GC/MS/MS‐method. During intravenous infusion of 30, 60 and 120 micrograms PGE1, endogenous plasma PGE1 concentrations increased from 1.7 +/‐ 0.8 to 4.2 +/‐ 1.1, 6.7 +/‐ 1.0 and 11.0 +/‐ 1.9 pg ml‐1 respectively. PGE0 plasma concentrations increased from endogenous levels of 1.3 +/‐ 1.0 pg ml‐1 to 7.6 +/‐ 2.1, 14.1 +/‐ 3.7 and 28.0 +/‐ 3.0 pg ml‐1 respectively, whilst 15‐keto‐PGE0 plasma concentrations increased from endogenous levels of 10.2 +/‐ 13.9 pg ml‐1 to 99.3 +/‐ 27.9, 190.4 +/‐ 52.5 and 357.2 +/‐ 72.6 pg ml‐1 respectively. Within the dose range of 30‐120 micrograms PGE1 2 h‐1 there was a linear increase of Cmax and AUC with the dose. The results of the analysis of variance after baseline and dose‐correction show a 90% confidence interval in the bioequivalence acceptance range of 80 to 125%.
Type of Medium:
Online Resource
ISSN:
0306-5251
,
1365-2125
DOI:
10.1111/bcp.1995.40.issue-3
DOI:
10.1111/j.1365-2125.1995.tb05784.x
Language:
English
Publisher:
Wiley
Publication Date:
1995
detail.hit.zdb_id:
1498142-7
SSG:
15,3
Bookmarklink